Looking to build in red-hot viral vector space, Thermo Fisher inks $878M deal for Belgian manufacturer's 2 plants
Between Covid-19 vaccines and gene therapies, the contract manufacturing market for viral vector tech has grown at a rapid clip. Thermo Fisher Scientific, already one of the biggest CDMOs on the block, has now made a move to buoy its EU footprint in that field.
Thermo Fisher will pay $878 million to acquire Henogen SA, Novasep’s viral vector manufacturing business, which comprises two Belgian locations in Seneffe and Gosselies that offer over 75,000 square feet of clinical and commercial manufacturing capacity, the Massachusetts company said Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.